CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Aug. 2026Education/Webinars

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.

Failure to identify surrogate decision makers on admission can delay care decisions, increase family conflict, create ethical and legal uncertainty, and lead to care that may not reflect the patient’s values. Early identification supports timely, coordinated, values-concordant care and reduces burden on families, clinicians, and institutions.

Upon completion of this activity, participants should be able to:

  • Identify appropriate surrogate decision makers and advance-directive documentation during the admission process.
  • Apply institutional and legal standards to determine decision-making authority when a patient lacks capacity.
  • Implement communication strategies that promote timely, values-concordant care and reduce conflict among patients, families, and healthcare teams.

Presenter:

  • Donna Durant, DNP, MSN, CRNP-FNP, Advanced Practice Provider Education Lead, Palliative Care Division of UPMC General Medicine, UPMC Presbyterian Hospital

Register Now

Provider is responsible for verifying CME eligibility.

This activity is approved for the following credit: AMA PRA Category 1 Credit™ and ANCC. Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.


Recent Announcements

Medicaid Renewal

Starting in 2027, some Medicaid recipients (ages 19–-64) will have new requirements to keep their coverage.
Aug. 2026Important Notices

Provider Directory Updates and Required Attestation

As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).
Aug. 2026Important Notices

Voluntary nationwide recall: Tyenne (Fresenius – August 2026)

Fresenius Kabi is recalling one lot, lot 16UI07, of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL) 20 mL vials. Tyenne is used for the treatment of certain arthritis conditions.
Aug. 2026Pharmacy Updates